GNS Healthcare Launches Computer Model of Disease Progression, Treatment Responses in Myeloma
A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to treatment in people with…
Myeloma
Reolysin-Kyprolis Combo Elicits Promising Clinical Responses in Phase 1B Trial
When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses…
FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients
Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan…
1,066 Myeloma Patients Answer HealthTree Survey of COVID-19’s Effects
Over some four weeks, 1,066 people with multiple myeloma took part in a survey sponsored by HealthTree to better understand how COVID-19 is affecting life…
FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing…
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with…
Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo
The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients…
Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials
Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat…
JNJ-4528 Continues to Show Strong, Durable Responses in Trial
Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with…
Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled
A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully enrolled,…
